HLA-G and neoplasm: In this context, a large body of research has demonstrated that blockade of HLA‐G and ILTs could restore the cytotoxicity of NK cells.75 For T cells, HLA‐G‐derived peptides HLA‐G146–154 and HLA‐G26–40 could effectively induce peptide‐specific CD8+ T cytotoxicity and tumor‐reactive CD4+ T‐cell responses, respectively, rendering the possibility of HLA‐G peptide‐based tumor immunotherapy.76, 77 Finally, targeting tumor‐specific HLA‐G to develop drug delivery systems has been carried out.